NCT05355155 is a Phase 2 clinical trial of Bevacizumab Biosimilar IBI305 in Post-orthotopic Liver Transplantation, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT05355155?

NCT05355155 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT05355155?

Interventions in NCT05355155: Bevacizumab Biosimilar IBI305.

What condition does NCT05355155 study?

NCT05355155 studies Post-orthotopic Liver Transplantation, Hepatocellular Carcinoma Recurrent.

Is NCT05355155 still recruiting?

NCT05355155 is currently status unknown. Last updated 11 May 2022.

Last reviewed 2022-05-11 · How we verify

NCT05355155

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation

Status unknown Phase 2 Last updated 11 May 2022

What this trial tests

Phase 2 trial testing Bevacizumab Biosimilar IBI305 in Post-orthotopic Liver Transplantation in 15 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
31 May 2023

31 December 2024

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 May 2022
Primary completion	31 May 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Bevacizumab Biosimilar IBI305 — full drug profile →

Conditions studied

Post-orthotopic Liver Transplantation — all drugs for Post-orthotopic Liver Transplantation →
Hepatocellular Carcinoma Recurrent — all drugs for Hepatocellular Carcinoma Recurrent →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 80, any sex, with Post-orthotopic Liver Transplantation or Hepatocellular Carcinoma Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single arm, single center, prospective and open exploratory study. About 15 patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation are expected to be enrolled.Patients will be treated with bevacizumab and FOLFOX4.Treatment was continued until disease progression, development of intolerable toxicities, death, withdrawal of consent, initiation of new antitumor therapy, whichever occurred first.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma.
Liang J, Bai Y, Ha FS, Luo Y, et al · · 2023 · cited 11× · PMID 36684055 · DOI 10.4251/wjgo.v15.i1.1
Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma.
Kapelanski-Lamoureux A, Lazaris A, Meti N, Metrakos P. · · 2025 · PMID 41375071 · DOI 10.3390/cancers17233870

Verify or expand the search:

Other trials of Bevacizumab Biosimilar IBI305

Trials testing the same drug.

NCT05507606 — Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations · Phase 2 · unknown
NCT04735861 — Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma · Phase 2 · completed

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05355155 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 11 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05355155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing